患有的成年人自我完成的患者报告的结果指标:一篇综述
Alison L Conquest1,2,3, Terence J O'Brien1,2,3,4, Patrick Kwan1,2,3,5,6
1Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Epilepsia open
|November 5, 2025
概括
患者报告的结果指标 (PROM) 是一个问卷,记录患者患的经历. 本综述确定并讨论了22个PROM,以帮助临床医生选择适当的研究和实践工具,改善患者护理.
科学领域:
- 神经学 神经学
- 患者报告的结果
- 医疗保健服务研究 医疗服务研究
背景情况:
- 影响全球6500万,被世界卫生组织认定为优先的神经系统疾病.
- 改善的治疗和护理是世卫组织跨部门全球行动计划 (IGAP) 的一个关键目标.
- 患者报告结果指标 (PROM) 评估患者的生活经历,包括生活质量,情绪和治疗副作用,并建议用于临床试验和实践.
研究的目的:
- 对临床研究和实践中使用的PROM进行叙事审查.
- 识别和总结常用的PROM在的优点和局限性.
- 为临床试验和常规实践选择PROM提供指导.
主要方法:
- 对PubMed和卫生监管机构的指导方针进行了叙述性审查.
- 确定了390个独特的PROM用于的环境.
- 总结了PROM选择的实际考虑,包括心理测量属性,PROM类型和收集优化.
主要成果:
- 确定和审查了22个常用于临床研究和实践的PROM.
- 讨论了这些PROM在四个领域的优势和局限性:生活质量,残疾/发作严重程度,情绪和药物不良影响.
- 强调了明智的PROM选择对于了解患者体验和为临床决策提供信息的重要性.
结论:
- 该审查作为在研究和临床实践中选择PROM的参考.
- 有效的PROM选择和应用可以增强对患者体验的理解,并改善临床决策.
- PROM有潜力改善病护理中的患者满意度,沟通和治疗监测.
更多相关视频
10:23Equipment Setup and Artifact Removal for Simultaneous Electroencephalogram and Functional Magnetic Resonance Imaging for Clinical Review in Epilepsy
Published on: June 23, 2023
2.6K
10:46Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
Published on: September 1, 2023
4.3K
相关概念视频
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
620
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
620